Form 4: Sarepta Therapeutics Executive Louise Rodino-Klapac Reports Stock Transaction
SEC Form 4 Filing
Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports disposition of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On March 4, 2024, Louise Rodino-Klapac, Head of R&D and CSO of Sarepta Therapeutics, Inc., disposed of 1,728 shares of common stock to cover tax withholding obligations.
- The shares were sold at a price of $125.32 per share.
- Following the transaction, Rodino-Klapac directly owns 69,494 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as this is a routine transaction related to tax obligations and doesn't reflect a significant change in the executive's holdings or outlook.
Industry Context
This is a routine Form 4 filing, reflecting a common practice where company shares are sold to cover tax obligations arising from the vesting of restricted stock units. It's a standard part of executive compensation and doesn't necessarily indicate a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/03/2021 | Date of grant for restricted stock units related to the tax withholding obligation. |
| 03/04/2024 | Date of the stock transaction (disposal of shares). |
| 03/06/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.